← Human Trials & Peer-Reviewed Studies
Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study
Plain-language guide to PMID 20884247 (2012): clinical trial, phase ii study of IGF-1 LR3 and Octreotide, insulin resistance, prediabetes & type 2 diabetes.
Key Facts
- PMID
- 20884247
- Journal
- Urologic oncology
- Year
- 2012
- Study type
- Clinical Trial, Phase II
- Authors
- Friedlander TW et al. (8 authors)
- DOI
- 10.1016/j.urolonc.2010.06.014
- Registered trial
- NCT00510224
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of IGF-1 LR3 and Octreotide in the context of insulin resistance, prediabetes & type 2 diabetes, published as a clinical trial, phase ii.
Insulin-like growth factor (IGF) mediated signaling has been implicated in the growth of many tumor types including prostate cancer, and it is hypothesized that lowering circulating IGF levels in men with castration resistant prostate cancer (CRPC) will slow tumor growth.
Who Took Part
The age groups tagged for this paper are middle-aged adults, older adults and people over 80, men only.
Eligible patients had progressive non-metastatic CRPC.
How the Study Was Run
Changes in PSA, IGF-1, IGF-2, IGF binding protein-1 (IGFBP-1), and IGFBP-3 were evaluated over time.
What Was Measured
Insulin-like growth factor (IGF) mediated signaling has been implicated in the growth of many tumor types including prostate cancer, and it is hypothesized that lowering circulating IGF levels in men with castration resistant prostate cancer (CRPC) will slow tumor growth.
Topics PubMed links to this paper include Antineoplastic Agents, Hormonal, Diarrhea, Enzyme-Linked Immunosorbent Assay, Fatigue, Flatulence, Insulin-Like Growth Factor Binding Protein 1 and Insulin-Like Growth Factor Binding Protein 3.
What This Means in Plain Language
This is a clinical trial, phase ii of IGF-1 LR3 and Octreotide in people with insulin resistance, prediabetes & type 2 diabetes.
Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2012 (Urologic oncology), a journal based in United States.
More context: the IGF-1 LR3 compound page and the Octreotide compound page, Insulin resistance, prediabetes & type 2 diabetes research.
Our Notes on the Compounds
IGF-1 LR3: A modified IGF-1 analog that escapes binding proteins, so it stays active ≥24 h.
Octreotide: An 8-amino-acid somatostatin analog (Sandostatin, Mycapssa) used for acromegaly and certain hormone-secreting tumors.
Related Pages
- Insulin resistance, prediabetes & type 2 diabetes research
- IGF-1 LR3 in the library
- Octreotide in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.